Complete remission seven years after treatment for metastatic malignant melanoma.

Journal Article (Clinical Trial;Journal Article;Multicenter Study)

BACKGROUND: In this study, the authors identified seven-year survivors after completion of the French multicenter Phase II trial of fotemustine for the treatment of metastatic malignant melanoma. METHODS: One hundred sixty-nine patients with metastatic malignant melanoma were included in this Phase II study. One hundred fifty-three patient records were evaluable with an overall response rate of 24.2%. RESULTS: Five of these patients are alive and in complete remission. One patient had a complete response after fotemustine administration and then relapsed. One patient had a partial response. Three patients had stable disease. These five patients underwent surgery for relapse or residual disease and subsequently achieved durable complete remission. CONCLUSIONS: Long term survival may be the outcome after surgical resection of residual metastatic melanoma after chemotherapy.

Full Text

Duke Authors

Cited Authors

  • Petit, T; Borel, C; Rixe, O; Avril, MF; Monnier, A; Giroux, B; Weil, M; Khayat, D

Published Date

  • March 1, 1996

Published In

Volume / Issue

  • 77 / 5

Start / End Page

  • 900 - 902

PubMed ID

  • 8608481

International Standard Serial Number (ISSN)

  • 0008-543X


  • eng

Conference Location

  • United States